Microvascular invasion risk scores affect the estimation of early recurrence after resection in patients with hepatocellular carcinoma: a retrospective study

Sheng Wang¹, Weizhi Zheng², Zhencheng Zhang³, Guo-hua Zhang¹*† and Dan-jiang Huang¹*†

Abstract

Background: Microvascular invasion (MVI) is a histological factor that is closely related to the early recurrence of hepatocellular carcinoma (HCC) after resection. To investigate whether a noninvasive risk score system based on MVI status can be established to estimate early recurrence of HCC after resection.

Methods: Between January 2018 to March 2021, a total of 108 patients with surgically treated single HCC was retrospectively included in our study. Fifty-one patients were pathologically confirmed with MVI and 57 patients were absent of MVI. Univariate and multivariate logistic regression analysis of preoperative laboratory and magnetic resonance imaging (MRI) features were used to screen noninvasive risk factors in association with MVI in HCC. Risk scores based on the odds ratio (OR) values of MVI-related risk factors were calculated to estimate the early recurrence after resection of HCC.

Results: In multivariate logistic regression analysis, tumor size > 2 cm (P = 0.024, OR 3.05, 95% CI 1.19–11.13), Prothrombin induced by vitamin K absence-II > 32 mAU/ml (P = 0.001, OR 4.13, 95% CI 1.23–11.38), irregular tumor margin (P = 0.018, OR 3.10, 95% CI 1.16–8.31) and apparent diffusion coefficient value < 1007 × 10⁻³mm²/s (P = 0.035, OR 2.27, 95% CI 1.14–7.71) were independent risk factors correlated to MVI in HCC. Risk scores of patients were calculated and were then categorized into high or low-risk levels. In multivariate cox survival analysis, only high-risk score of MVI was the independent risk factor of early recurrence (P = 0.009, OR 2.11, 95% CI 1.20–3.69), with a sensitivity and specificity of 0.52, 0.88, respectively.

Conclusion: A risk score system based on MVI status can help stratify patients in high-risk of early recurrence after resection of HCC.

Keywords: Microvascular invasion, Hepatocellular carcinoma, Risk score, Recurrence

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/-zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
pathological factors of HCC, including low tumoral differentiation, microvascular invasion, is high-risk for early recurrence after resection [3–5].

Microvascular invasion (MVI) is one of the most important histological features that is closely related to postoperative early recurrence of HCC [6]. The treatments decision making may be changed for HCC patients with MVI [7, 8]. Though MVI can only be identified by histology, considerable efforts have been made to provide a noninvasive method to predict MVI status of HCC. Currently, α-fetoprotein (AFP) and Prothrombin induced by vitamin K absence-II (PIVKA-II) are important serum tumor markers in the detection of HCC [9–12]. The elevated serum level of PIVKA-II is associated with MVI and tumor recurrence [12]. The radiological methods including morphologic features and quantitative imaging parameters have been widely explored for predicting MVI status in HCC [13–18]. Some imaging features such as the tumor size, irregular shape, tumoral or peritumoral enhancement pattern, capsule appearance et al., are valuable characteristics of evaluating MVI. The further quantitative analyses of the radiomics or deep learning approaches are promising but technically complex in regarded as “black box” [19, 20]. Unfortunately, a reliable predictive model of MVI in consensus for estimating recurrence-free survival of patients after resection of HCC for an easier clinical use is still in lack.

Several previous studies have established a predictive model derived from MRI variables to directly estimate the risk of early recurrence after resection of HCC [21–24]. However, in these MR imaging-based models, the relationship between the risk factors and MVI was unclear, so these risk factors cannot replace the crucial role of pathologically determined MVI status for predicting early recurrence. Whether a predictive model of MVI can be used to predict postoperative early recurrence needs to be identified. We proposed that a simplified point scale can reflect the impact of each variable on MVI for patient risk stratification of early recurrence and thus benefit patients from therapeutic decision making.

In our study, we aimed to develop a noninvasive risk score system based on MVI to establish a predictive model for prognostic stratification of early recurrence in HCC patients after resection.

Materials and methods

Study population

This is a retrospective study with ethics committee approved by the local institutional review board (approval number 2020-KY002-01) and the requirement for written informed consent waived. Between January 2018 to March 2021, 143 patients in suspicious of having HCCs were consecutively included in our study, after reviewing the institutional radiological and histological database. Inclusion criteria: (1) pathological diagnosis of single HCC after surgery in confirmation with or without MVI; (2) having preoperative MRI and laboratory tests no more than 2 weeks before surgery; (3) receiving no preoperative adjuvant treatments. 35 patients were excluded for: (1) 3 patients having two or multiple HCCs; (2) 6 patients having no preoperative MRI; (3) 15 patients having preoperative adjuvant TACE or targeted therapies; (4) 9 patients having been using relevant drugs (e.g. vitamin K and warfarin) that may affect the results of the PIVKA-II test; (5) 2 patients followed up for less than 6 months (Fig. 1). Finally, a total of 108 patients with pathologically single HCC was included in our analysis, with 51 patients were presence of MVI and 57 were absence of MVI.

Baseline characteristics and imaging variables

The baseline characteristics of patients including age, gender, etiology, alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum alpha-fetoprotein (AFP), PIVKA-II level and maximum tumor diameter were recorded. The PIVKA-II level was measured on an instrument (ARCHITECT i 2000SR) by using the same batch of PIVKA-II test reagents manufactured by the company (Abbott, USA). A PIVKA-II level > 32 mAU/ml is considered positive.

First, two experienced radiologists in consensus evaluated the following MR imaging features: (1) the maximum tumor diameter, measured on the pre-contrast phase during dynamic contrast-enhanced MRI; (2) tumor margin, categorized as smooth and irregular tumor margin; (3) presence or absence of capsule enhancement; (4) apparent diffusion coefficient (ADC) values, measured three times at each section of the whole tumor, and the average value of the three times was calculated. Risk scores were simplified by rounding odds ratio (OR) values of risk factors of MVI to nearest half for establishing a predictive model of early recurrence. To test the reproducibility of the risk score system, the risk score of MVI for each HCC patient based on significant imaging features was assessed by a third radiologist independently for evaluating the inter-observer agreement.

MRI protocol

All MRI examinations were performed using a German Siemens 1.5 T magnetic resonance scanner with a body phased array coil. The standard imaging protocol included transverse T1-weighted fat suppression imaging (repetition time (TR):132.00ms, echo time (TE):5.09ms, bandwidth (BW):179.00, flip angle (FA):60.00°, slice thickness: 6.00 mm, layer spacing: 1.80 mm), T2-weighted cross-sectional fat suppression imaging
A total of 143 patients with pathologically confirmed HCC Between January 2018 to March 2021 were consecutively included in our study.

Excluded patients:
1. Patients having two or multiple HCCs (n=3)
2. Patients having no preoperative MRI (n=6)
3. Patients having preoperative adjuvant TACE or targeted therapies (n=15)
4. Patients having been using relevant drugs (e.g. vitamin K and warfarin) that may affect the results of the PI/PIKA-II test (n=9)
5. Patients followed up for less than 6 months (n=2)

Finally included 108 HCC (n=108)

MVI (+) (n=51)
MVI (-) (n=57)

Fig. 1 Flowchart of excluded patients in our study

(TR:5500.18ms, TE:101.00ms, BW: 260.00, FA:140.00°, slice thickness:6.00 mm, layer spacing:1.80 mm), diffusion-weighted imaging (b=800s/mm²) and apparent diffusion coefficient (ADC, TR:5574.23ms, TE:72.00ms, BW:1736.00, FA: 90.00, slice thickness:6.00 mm, layer spacing:1.80 mm). The contrast agent gadopentetate was injected intravenously at a rate of 2 ml/s at 0.2 mmol/kg and flushed with saline. Scans of arterial, portal and delayed phases were taken at 22s, 60 and 180s post-injection, respectively.

Pathological diagnosis of MVI
The “7-point” baseline sampling method was used, with 1:1 sampling of tumor and peritumoral liver tissue at 12, 3, 6 and 9 points of the tumor [7]. The pathological diagnosis report included description of the gross specimen, immunohistochemical staining, and MVI status. MVI was diagnosed as presence of nesting clusters of tumor cells in the portal vein branches, hepatic vein or endothelium-lined vasculature under the microscope.

Follow-up
For HCC patients after resection, ultrasound and serum AFP test were performed every 3 months during the first 2 years and every 6 months thereafter during follow-up. All patients were follow-up for at least 6 months until the end of our study. Dynamic contrast-enhanced CT/MRI or 18 F-fluorodeoxyglucose positron emission tomography (PET-CT) would be performed for further evaluation if patients have suspicious recurrence detected on US or with elevated AFP during follow-up. The intrahepatic recurrence was identified by either pathological findings or typical imaging features of HCC [25, 26]. Early recurrence was defined as intrahepatic recurrence during the first 2 years after resection of HCC [3].

Statistical analysis
Student’s t-test was used for comparison between normally distributed variables that expressed as mean ± standard deviation. Mann–Whitney U test were used for comparison between non-normally distributed variables that expressed as median with range in parentheses. Chi-square test was used for comparison between categorical groups. Univariate and multivariate logistic regression was applied to screen the independent risk factors of MVI and early recurrence. OR with 95% confidence interval (95% CI) were calculated. Inter-correlation coefficient (ICC) of risk scores was calculated between two observers. Risk scores with ICC value greater than 0.75 were considered of good reproducibility [27]. The receiver operating characteristic (ROC) curve of ADC value with area under ROC curve (AUC) and the cutoff value calculated. The sensitivity, specificity of risk score levels were calculated. P value < 0.05 was considered a statistically significant
difference. SPSS software (version 21.0; SPSS, Chicago, Ill) was used for data analysis.

**Results**

**Patient characteristics**

A total of 108 HCC patients (94 males and 14 females) were included in our study. Among the 108 patients, 51 patients were presence of MVI and 58 patients were absence of MVI, with an average age of 61 years. The mean follow-up time of all 108 HCC patients was 16.9 ± 9.1 months (range: 6–36 months). During follow-up, 46 (42.6%) patients had early recurrence of HCC after resection, with an average time to early recurrence of 13.3 ± 6.5 months.

**Risk factors of MVI**

The demographic, laboratory and imaging characteristics were demonstrated in Table 1. The results showed that tumor diameter, serum PIVKA-II level, tumor shape and ADC values were significantly different between MVI positive and negative groups. The AUC of ADC value for predicting MVI in HCC is 0.849 (0.776–0.922) with a cut-off value of $1007 \times 10^{-3} \text{mm}^2/\text{s}$. In univariate analysis, the risk factor of tumor size > 2 cm, PIVKA-II > 32 mAU/ml, irregular shape, ADC < $1007 \times 10^{-3} \text{mm}^2$ and capsule enhancement were associated with MVI in HCC patients (all $P < 0.05$). In multivariate analysis, tumor size > 2 cm ($P = 0.024$, OR 3.05, 95% CI 1.19–11.13),

| Table 1 | Comparisons of baseline variables between MVI-positive and MVI-negative groups |
|---------|----------------------------------|
| Variable                          | MVI (+)          | MVI (-)          | $P$ value |
| Age (years)                        | 61 ± 11          | 61 ± 9           | 0.969     |
| Sex                                |                  |                  | 0.355     |
| Male                               | 46               | 48               |           |
| Female                             | 5                | 9                |           |
| Etiology                           |                  |                  | 0.867**   |
| Hepatitis B virus                  | 47               | 53               |           |
| Hepatitis C virus                  | 2                | 3                |           |
| None or other                      | 2                | 1                |           |
| Aspartate aminotransferase (IU/L)  | 40.5 ± 30.7      | 33.5 ± 33.2      | 0.259     |
| Alanine aminotransferase (IU/L)    | 39.7 ± 35.0      | 32.4 ± 38.9      | 0.310     |
| Histological grade                 |                  |                  | 0.642     |
| Low                                | 26               | 31               |           |
| High                               | 21               | 30               |           |
| Tumor diameter (cm)                | 46.9 ± 28.6      | 23.3 ± 10.5      | < 0.001   |
| > 2 cm                             | 34               | 10               | < 0.001   |
| ≤ 2 cm                             | 17               | 47               |           |
| Alpha-fetoprotein (ng/ml)          | 742.4 (1.5-27738.3) | 172.7 (1.2-3634.5) | 0.093*    |
| ≥ 20 ng/ml                         | 22               | 20               | 0.433     |
| < 20 ng/ml                         | 29               | 37               |           |
| PIVKA-II (mAU/ml)                  | 3526.4 (16.7-30000) | 412.8 (12.1-14817) | < 0.001*  |
| > 32 mAU/ml                        | 40               | 18               | < 0.001   |
| ≤ 32 mAU/ml                        | 11               | 39               |           |
| Tumor shape                        |                  |                  | 0.001     |
| Irregular                          | 29               | 15               |           |
| Smooth                             | 22               | 42               |           |
| ADC ($\times 10^{-3} \text{mm}^2/\text{s}$) | 930.7 ± 102.3 | 1059.5 ± 127.4 | < 0.001   |
| Capsule enhancement                |                  |                  | 0.103     |
| Presence                           | 33               | 28               |           |
| Absence                            | 18               | 29               |           |

* $P$ value were calculated by using Mann-Whitney U test
** Data were compared using the Fisher's exact test

PIVKA-II: prothrombin induced by vitamin-K-absence-II; ADC: apparent diffusion coefficient
PIVKA-II $>$ 32 mAU/ml ($P = 0.001$, OR 4.13, 95% CI 1.23–11.38) and ADC $<$ 1007 $\times$ 10$^{-3}$ mm$^2$/s ($P = 0.035$, OR 2.27, 95% CI 1.14–7.71) were independent risk factors of MVI (Table 2). Table 3 demonstrated that the ICC of risk scores from significant imaging features in multivariate analysis was 0.881 (95% CI 0.830–0.917).

### Prognostic stratification based on risk score

The risk score was weighted based on the OR values of MVI in multivariate analysis. The risk score of tumor size $>$ 2 cm, PIVKA-II $>$ 32 mAU/ml, irregular tumor margin and ADC $<$ 1007 $\times$ 10$^{-3}$ mm$^2$/s was 3, 4, 3, 2 points, respectively. The risk factors of tumor size $>$ 2 cm, PIVKA-II $>$ 32.01 mAU/ml, ADC $<$ 1007 $\times$ 10$^{-3}$ mm$^2$/s and high histological grade were significantly different between patients with or without early recurrence while irregular tumor shape showed no statistical significance (Table 4). The risk score ranged from 0 to 12 points. Patients were then categorized into low-risk (risk score: 0–7 points) and high-risk (risk score: 8–12 points) levels. The high or low-risk score level can significantly stratified prognostic difference of early recurrence ($P < 0.001$), with a relative low sensitivity of 0.52 but high specificity of 0.88 for estimating early recurrence. Among 108 patients

### Table 2  Univariate and Multivariate analysis of risk scores for MVI in HCC.

|               | Univariate | $P$  | Multivariate | $P$  | Risk score |
|---------------|------------|------|--------------|------|------------|
|               | OR (95% CI)|      | OR (95% CI)  |      |            |
| Age           | 0.98 (0.95–1.02) | 0.337 |               |      |            |
| Sex           | 0.13 (0.02–1.15)  | 0.067 |               |      |            |
| Hepatitis B virus | 1.02 (0.97–1.04) | 0.967 |               |      |            |
| Size $>$ 2 cm | 9.40 (3.83–23.05) | $<$ 0.001 | 3.05 (1.19–11.13) | 0.024 | 3          |
| Alpha-fetoprotein $\geq$ 20 ng/ml | 1.40 (0.65–3.05) | 0.392 |               |      |            |
| PIVKA-II $>$ 32 mAU/ml | 7.88 (3.30–18.81) | $<$ 0.001 | 4.13 (1.23–11.38) | 0.001 | 4          |
| Irregular Shape | 3.69 (1.64–8.29) | 0.002 |               |      |            |
| ADC $<$ 1007 $\times$ 10$^{-3}$ mm$^2$/s | 3.97 (1.78–8.85) | 0.001 | 2.27 (1.14–7.71) | 0.035 | 2          |
| Capsule enhancement | 0.51 (0.36–0.93) | 0.034 |               |      |            |
| Alanine aminotransferase | 1.01 (0.94–1.02) | 0.324 |               |      |            |
| Aspartate aminotransferase | 1.01 (0.99–1.08) | 0.279 |               |      |            |

PIVKA-II: prothrombin induced by vitamin-K-absence-II; ADC: apparent diffusion coefficient; OR: odds ratio; 95% CI: 95% confidence interval

### Table 3  Reproducibility in the evaluation of risk scores between two observers

|               | Observer 1 | Observer 2 | ICC (95% CI) |
|---------------|-----------|------------|--------------|
| Number of patients |           |            |              |
| Size $>$ 2 cm  | 44        | 51         |              |
| PIVKA-II $>$ 32 mAU/ml | 58        | 58         |              |
| Irregular Shape | 44        | 47         |              |
| ADC $<$ 1007 $\times$ 10$^{-3}$ mm$^2$/s | 51        | 56         |              |
| High-risk of MVI (8–12 point) | 38        | 40         |              |
| Low-risk of MVI (0–7 point) | 70        | 68         |              |
| Risk score    | 5.5 ± 4.1 | 5.9 ± 3.9  | 0.881 (0.830–0.917) |

ICC: Inter-correlation coefficient

### Table 4  Comparisons of MVI-related risk factors between presence and absence of early recurrence of HCC after resection

| Risk factors               | No. of patients | Early recurrence | No early recurrence | $P$  |
|----------------------------|-----------------|------------------|---------------------|------|
| Tumor size $>$ 2 cm        | 44              | 25               | 19                  | 0.048|
| PIVKA-II $>$ 32.01 mAU/ml  | 58              | 33               | 25                  | 0.010|
| Irregular Shape            | 44              | 22               | 22                  | 0.439|
| ADC $<$ 1007 $\times$ 10$^{-3}$ mm$^2$/s | 51        | 31               | 20                  | 0.002|
| High histological grade    | 47              | 31               | 16                  | 0.006|
| Risk level of MVI*          |                 |                  |                     | $<$ 0.001|
| High-risk (8–12 point)     | 38              | 29               | 9                   |      |
| Low-risk (0–7 point)       | 70              | 26               | 44                  |      |

PIVKA-II: prothrombin induced by vitamin-K-absence-II; ADC: apparent diffusion coefficient
of HCC, 70 patients had low-risk scores of MVI (Fig. 2) and 26 of them (26/70, 37.1%) had early recurrence; 38 patients had high-risk scores of MVI and 29 of them (29/38, 76.4%) had early recurrence (Fig. 3). In univariate cox survival analysis, tumor size > 2 cm, PIVKA-II > 32 mAU/ml, ADC < 1007 × 10⁻³mm², high histological grade and high-risk score of MVI were statistically significant risk factors of early recurrence. In multivariate cox survival analysis, only high-risk score of MVI was independent risk factor of early recurrence (P = 0.009, OR 2.11, 95% CI 1.20–3.69) (Table 5). The Kaplan-Meier curves in Fig. 4 showed that the RFS in high-risk group of MVI was worse than low-risk group of MVI (P = 0.0014).

Discussion

Our study developed a simple risk score based on MVI status by evaluation of preoperative radiological and laboratory characteristics. A high-risk score of MVI can provide a reliable prognostic stratification in early recurrence of HCC after resection.

In recent years, many scholars have paid attention to the noninvasive evaluation of MVI in HCC, because MVI is one of the most important pathological factors in association with aggressiveness of tumor and postoperative early recurrence.

Our study found that PIVKA-II-positive HCCs were more likely to have MVI than PIVKA-II-negative HCCs. PIVKA-II promotes proliferation of HCC cells and induces angiogenesis in surrounding liver tissue, thus promote vascular invasion of HCC [28, 29]. Previously, Yu et al. [15] found that the sensitivity of PIVKA-II in diagnosing HCC was higher than that of AFP, especially in early-stage HCC. The elevated level of PIVKA-II tests was associated with MVI in HCC [9, 12], which is consistent with our findings. In our multivariate analysis, the PIVKA-II showed the highest OR value among the risk factors, indicating that PIVKA-II was the most important risk factor related to MVI in HCC.

Our risk score system contained some important imaging features in predicting MVI status of HCC. Consistent with previous reports, the larger tumor size and irregular tumor margin were proposed as significant risk factors that related to MVI in HCC. As the tumor size increases during progresses, the risk of MVI and intrahepatic metastasis increases. Pawlik et al. [16] investigated...
the relationship between the tumor size in 1073 HCC patients and MVI, and found that single HCC larger than 5 cm had significantly increased incidences of MVI. The tumor margin evaluated on MRI reflects the pathological characteristics of gross appearance. The gross types of “nodular with extranodular growth” and “multinodular confluent type” showing irregular tumor margin on MRI may have a higher incidence of MVI in HCC [30, 31].

The quantitative parameter of ADC value was included in our risk score because ADC reflects the extent of diffusion hindrance and mobility of water molecules and indicates tumor cellularity and microenvironment [32]. Previously, Suh et al. [14] found that an ADC value $\leq 1.11 \times 10^{-3}\text{mm}^2/\text{s}$ was an independent risk factor for predicting MVI with a high sensitivity and specificity of 93.5% and 72.2%, respectively. Xu et al. [15] reported that an ADC value $\leq 1.227 \times 10^{-3}\text{mm}^2/\text{s}$ ($b = 500\text{s/\text{mm}^2}$) was an independent risk factor for predicting MVI in HCC smaller than 2 cm, with a sensitivity and specificity of 66.7% and 78.6%, respectively. In our risk score, ADC showed the lowest OR values among the risk factors, the reason may be that ADC values vary widely during measurement and may not be adapted in generalization [33].

Many previous predictive models of MVI may have limited clinical utility because most models are not applicable to the prognostic stratification of early recurrence. Also, several predictive models of early recurrence have been proposed but the relationship between predictive factors of early recurrence and MVI may be lack of interpretation. Our proposed risk score based on MVI status is simple and easily to be evaluated, which may help clinicians to estimate the prognostic stratification of early recurrence after resection with a pathology-based explanation. Patients eligible for surgery with a high-risk score of MVI may have a higher rate of early recurrence so that the adjuvant therapy may be needed to be considered.

Table 5 Cox survival analysis of MVI-related risk factors and scores for early recurrence of HCC after Resection

|                | Univariate       |          |          |         |          |          |         |         |
|----------------|------------------|----------|----------|---------|----------|----------|---------|---------|
|                | HR (95% CI)      | P        | HR (95% CI) | P        |          |          |         |         |
| Size > 2 cm    | 1.74 (1.02–2.96) | 0.041    | 1.30 (0.56–3.05) | 0.539    |          |          |         |         |
| PIVKA-II > 32.01 mAU/ml | 1.93 (1.08–3.46) | 0.027    | 1.39 (0.62–3.12) | 0.427    |          |          |         |         |
| Irregular Shape| 1.40 (0.81–2.41) | 0.224    |          |          |          |          |         |         |
| ADC < $1007 \times 10^{-3}\text{mm}^2/\text{s}$ | 1.95 (1.13–3.36) | 0.016    | 1.71 (0.93–3.14) | 0.082    |          |          |         |         |
| High histological grade | 1.82 (1.06–3.11) | 0.028    | 1.34 (0.50–3.56) | 0.504    |          |          |         |         |
| High-risk score of MVI | 2.30 (1.35–3.94) | 0.002    | 2.11 (1.20–3.69) | 0.009    |          |          |         |         |

PIVKA-II: prothrombin induced by vitamin-K-absence-II; ADC: apparent diffusion coefficient; HR: Hazard ratio

Fig. 3 A 56-year-old patient with the HCC in the right lobe of liver were histologically confirmed of presence of MVI (risk score of 12 points) and had early recurrence in 8 months after resection. A Pre-contrast phase; B Arterial phase; C Venous phase; D high b value map of DWI; E) ADC map; F presence of MVI under the microscope.
Our study has limitations. First, due to the small sample size in this retrospective study, selective bias cannot be avoided. Only solitary HCC was enrolled in our study. Second, some other risk factors of MVI were previously reported but were not included in our analysis. In the limited sample size, we selected some commonly used features that can be easily evaluated to facilitate a clinical use. Third, the risk score was established based on MVI status to provide a prognostic stratification of HCC patients. Whether there was potential intrahepatic metastasis or biliary infiltration indicating microinvasion in association with early recurrence was unclear and intraoperative ultrasound would be suggested for further evaluation [34]. Finally, our risk score is preliminary and needs further external validation with use of prospective cohort.

In conclusion, we developed a risk score system based on MVI status of HCC by integrating the noninvasive radiological and laboratory features to provide a stratification of patients in high-risk of early recurrence after resection, which is preliminary and needs further validation.

Abbreviations
MVI: Microvascular invasion; HCC: Hepatocellular carcinoma; AFP: Alpha-fetoprotein; PIVKA-II: Prothrombin induced by vitamin K absence-II; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; OR: Odds ratio; PPV: Positive predictive value; NPV: Negative predictive value; ADC: Apparent diffusion coefficient; BW: Bandwidth; FA: Flip angle.
**Competing interests**

All authors declare no competing interests.

**Author details**

1. Department of Radiology, Taizhou First People's Hospital, 218 Hengjie Rd., Dongcheng Street, Huangyan District, Taizhou City 318020, Zhejiang Province, China.
2. Department of Pathology, Taizhou First People's Hospital, Taizhou City 318020, Zhejiang Province, China.
3. Department of Laboratory, Taizhou First People's Hospital, Taizhou City 318020, Zhejiang Province, China.

**Received:** 26 January 2022  **Accepted:** 15 November 2022

**Published online:** 22 November 2022

**References**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018. CA Cancer J Clin. 2018;68(6):394–424.
2. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.
3. Imamura H, Matsuoka Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawakita S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200–7.
4. Park JH, Koh KC, Choi MS, Lee JH, Yoo BC, Paik SW, Rhee JC, Joh JW. Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma. Am J Surg. 2006;192(1):29–33.
5. Kamijima T, Nakanishi K, Yogo K, Kamachi H, Tahara M, Kikasaka T, Tsuuga Y, Todo S, Taketomi A. Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma. World J Surg Oncol. 2012;10:107.
6. Gouw AS, Balabaud C, Kusano H, Todo S, Ichida T, Kojiro M. Markers for carcinoid diagnosis and prediction of microvascular invasion. J Hepatol. 2015;62(4):848–54.
7. Nara S, Shimada K, Sakamoto Y, Esaki M, Kishi Y, Kosuge T, Ojima H. PIVKA-II as a potential New Biomarker for Hepato-Carcinoma. 2013;60(124):825–36.
8. Sugawara Y, Minagawa M, Takayama T, Kawasaki S, et al. Significance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinoma. In Vivo. 2018;32(6):1551–4.
9. Han J, Li ZZ, Xing H, Wu H, Zhu P, Lau WY, Zhou YH, Gu WM, Wang H, Chen TH, et al. The impact of resection margin and microvascular invasion on long-term prognosis after curative resection of hepatocellular carcinoma: a multi-institutional study. HPB (Oxford). 2019;21(8):962–71.
10. Pote N, Cauchy F, Albuquerque M, Voitot H, Belghiti J, Castera L, Puy H, Bedossa P, Paradis V. Performance of PIvka-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol. 2015;62(4):848–54.
11. Fan LF, Zhao WC, Yang N, Yang GS. Alpha-fetoprotein: the predictor of microvascular invasion in solitary small hepatocellular carcinoma and criterion for anatomic or non-anatomic hepatic resection. Hepatogastroenterology. 2013;60(124):825–36.
12. Svobodova S, Karlkova M, Topolcan O, Pecen L, Pestova M, Kott O, Treska T, Slouka D, Kucera R. PIVKA-II as a potential New Biomarker for Hepato-Carcinoma – A Pilot Study. In Vivo. 2018;32(6):1551–4.
13. Kim H, Park MS, Choi JY, Park VN, Kim MJ, Kim KS, Choi JS, Han HK, Kim E, Kim KW. Can microvessel invasion of hepatocellular carcinoma be predicted by preoperative MRI? Eur Radiol. 2009;19(7):1744–51.
14. Suh YJ, Kim MJ, Choi JY, Park MS, Kim KW. Preoperative prediction of the microvascular invasion of hepatocellular carcinoma with diffusion-weighted imaging. Liver Transpl. 2012;18(10):1171–8.
15. Xu P, Zeng M, Lu X, Shan Y, Xu C, Lin J. Microvascular invasion in small hepatocellular carcinoma: is it predictable with preoperative diffusion-weighted imaging? J Gastroenterol Hepatol. 2014;29(2):330–6.
16. Pavlik-TM, Delman KA, Vauthery JN, Nagorny DM, Ng KJ, Ikai I, Yamaoka Y, Belghiti J, Lauwers GY, Poon RT, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 2005;11(9):1086–92.
17. Wang WT, Yang L, Yang ZX, Hu XX, Ding Y, Yan X, Fu CX, Grimm R, Zeng MS, Rao SX. Assessment of microvascular invasion of hepatocellular carcinoma with diffusion kurtosis imaging. Radiology. 2018;286(2):571–80.
18. Ryu T, Takami Y, Wada Y, Tateishi M, Hara T, Yoshitomi M, Momosaki S, Yasumori K, Saitsu H, Okuda K. A clinical Scoring System for Predicting Microvascular Invasion in patients with Hepatocellular Carcinoma within the Milan Criteria. J Gastrointest Surg. 2019;23(4):779–87.
19. Song D, Wang Y, Wang W, Yang C, Li Z, Zhu K, Lv M, Gao Q, Zhou J, Fan J, et al. Using deep learning to predict microvascular invasion in hepatocellular carcinoma based on dynamic contrast-enhanced MRI combined with clinical parameters. J Cancer Res Clin Oncol. 2021;147(12):3577–67.
20. Price WN. Big data and black-box medical algorithms. Sci Transl Med 2018, 10(471).
21. An C, Kim DW, Park YN, Chung YE, Rhee H, Kim MJ. Single Hepatocellular Carcinoma: preoperative MR Imaging to predict early recurrence after curative resection. Radiology. 2015;276(2):433–43.
22. Kim S, Shin J, Kim DY, Choi GH, Kim MJ, Choi JY. Radiomics on Gadoxetic Acid-Enhanced magnetic resonance imaging for prediction of postoperative early and late recurrence of single Hepatocellular Carcinoma. Clin Cancer Res. 2019;25(13):3847–55.
23. Shan QY, Hu HT, Feng ST, Peng ZP, Chen SL, Zhou QL, Xu XY, Lu MD, Wang YW, et al. CT-based percutaneous radiomics signatures to predict early recurrence in hepatocellular carcinoma after curative tumor resection or ablation. Cancer Imaging. 2019;19(1):11.
24. Zhao Y, Wu J, Zhang Q, Hua Z, Qi W, Wang N, Lin T, Sheng L, Cui D, Liu J, et al. Radiomics Analysis based on Multiparametric MRI for Predicting Early recurrence in Hepatocellular Carcinoma after partial Hepatectomy. J Magn Reson Imaging. 2021;53(4):1066–79.
25. European Association for the Study of the Liver. Electronic address eee, European Association for the study of the L: EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
26. Cherymyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, Kono Y, Do RK, Mitchell DG, Sigal AG, et al. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk patients. Radiology. 2018;289(3):816–30.
27. Leijenaar RT, Carvalho S, Velazquez ER, van Elmpt WJ, Parmar C, Hoekstra OS, Hoekstra CJ, Boel RA, Dekker AL, Gillies RJ, et al. Stability of FDG-PET Radiometrics features: an integrated analysis of test-retest and inter-observer-variability. Acta Oncol. 2013;52(7):1391–7.
28. Fujikawa T, Shiraha H, Ueda N, Takaoka N, Nakashiti Y, Matsuoe N, Tanaka S, Nishina S, Suzuki M, Takaki A, et al. Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration. J Biol Chem. 2007;282(12):7471–8.
29. Gao FJ, Cui SX, Chen MH, Cheng YN, Sun LR, Ward SG, Kokudo N, Tang W, Xu QJ. Des-gamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cells. Life Sci. 2008;83(23–24):815–20.
30. Zhao WC, Fan LF, Yang N, Zhang HB, Chen BD, Yang GS. Preoperative predictors of microvascular invasion in multinodular hepatocellular carcinoma. Eur J Surg Oncol. 2013;39(8):858–64.
31. Rodriguez-Peralvez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol 2013;20(1):325–39.
32. Le Bihan D. Apparent diffusion coefficient and beyond: what diffusion MR imaging can tell us about tissue structure. Radiology. 2013;268(2):318–22.
33. Jensen JH, Helgerson JA, Ramani A, Lu H, Kaczynski K. Diffusional kurtosis imaging: the quantification of non-gaussian water diffusion by means of magnetic resonance imaging. Magn Reson Med. 2005;53(6):1452–40.
34. Yamashita Y, Tsujita E, Takeishi K, Fujirawa M, Kira S, Mori M, Aishima S, Takeotomi A, Shirabe K, Ishida T, et al. Predictors for microinvasion of small hepatocellular carcinoma </s>